Wanbury Ltd

Wanbury Management Change

Wanbury Limited announced the appointment of ABK & Associates as Cost Auditor and the re-appointment of Mohan Kumar Rayana as Executive Director.

Wanbury Annual General Meeting

Wanbury Limited held its 38th Annual General Meeting on September 24, 2026. Shareholders approved financial statements, director re-appointments, and cost auditor remuneration ratification.

Wanbury Annual General Meeting

Wanbury Limited has issued a notice for its Annual General Meeting scheduled on September 24, 2026, to transact various business resolutions.

Value

₹0.04 Cr

Wanbury Annual General Meeting

Wanbury Limited has scheduled its 38th Annual General Meeting for September 24, 2026. The meeting will address ordinary business, director re-appointments, and cost auditor remuneration.

Wanbury Product Launch

Wanbury Limited received EDQM approval for Rivaroxaban API. The company also obtained USFDA DMF clearances for Paroxetine HCI and Metformin HCI.

Wanbury Results Update

Wanbury reported Q1 FY27 financial results in a press release. The company also completed a Rs. 205 crore debt refinancing, improving its borrowing profile.

Value

₹205.0 Cr

Wanbury Employee Stock Options

Wanbury Limited allotted equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's total paid-up share capital.

Wanbury Management Change

Wanbury Limited has announced the re-appointment of Mr. Mohan Kumar Rayana as an Executive Director, effective August 21, 2026, for a 60-month term.

Wanbury Q1 FY27 Results: Net Profit ₹3.2 Cr, Down 76.3% YoY

Wanbury Ltd reported revenue from operations of ₹165.6 Cr (+1.5% YoY) and net profit of ₹3.2 Cr (-76.3% YoY) for Q1 FY27.

Key figure

Net profit ₹3.2 Cr · -76.3% YoY

Wanbury Board Meeting Date

Wanbury Limited has scheduled a board meeting for August 11, 2026, to consider its unaudited standalone financial results for the quarter ended June 2026.

Wanbury Business Update

Wanbury Limited received a 'No DMF deficiency' letter from the USFDA for multiple ANDAs. This clearance facilitates expansion into the South Korean API market.

Wanbury Business Update

Wanbury Limited announced that the USFDA completed a cGMP inspection at its Tanuku facility, resulting in a Form 483 with six observations.

Wanbury Price Movement Clarification

Wanbury Limited clarified that recent stock price increases are entirely market-driven. The company confirmed no undisclosed material information exists that could impact trading activity.

Wanbury Debt & Borrowing: ₹180 Cr

Wanbury Limited approved the early redemption of Rs. 180 Crore worth of 12.5% Non-Convertible Debentures. This full redemption will be completed before the February 2030 maturity date.

Value

₹180.0 Cr

Wanbury Share Pledge

Wanbury Ltd disclosed Catalyst Trusteeship Ltd, as debenture trustee, released a pledge on 85,20,330 shares on July 6, 2026. The release lowers equity encumbrance.